Dear Editor,
We have read the research proposal Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial by Ueda S. et al., with great interest. The authors presented a clinical trial protocol proposal to compare the efficacy of two DPP-IV inhibitors, i.e., anagliptin and sitagliptin on LDL cholesterol who are not controlled on statin therapy after ≥ 8 weeks in type 2 diabetes mellitus patients (T2DM) and atherosclerotic vascular lesions [1] . We would like to request the authors to clarify or elucidate the following points for our further understanding.
Firstly, the effect of drug varies in different individuals based on the number of factors and it can be explained by dose-response curve [2] . The authors mentioned that after fulfilling the eligibility criteria, patients will be randomized to either anagliptin 100 mg b.i.d. or sitagliptin 50 mg q.d. However, the recommended starting dose of anagliptin is 100 mg b.i.d. [3] and sitagliptin 100 mg q.d. [4] . Hence, the efficacy of anagliptin may be superior to that of sitagliptin in terms of reduction in LDL-C and HbA1c.
Secondly, DPP-IV inhibitors are known for its pancreatitis condition [5] ; however, the test for its confirmation and exclusion of those patents is not included in the eligibility criteria.
We would be highly obliged for your kind consideration of the abovementioned clarifications in your article to understand more beneficial effects of DPP-IV inhibitors in T2DM patients with atherosclerotic vascular lesions.
